clinical trial · NCT05894928
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
Eli Lilly and Company·phase1·completed·n = 21
HealthyLOXO-783Cholestyramine
brief summary
The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.
started
Jun 7, 2023
primary completion
Jul 9, 2023
completion
Jul 9, 2023
last updated
Sep 26, 2023
official title
A Phase 1 Study to Investigate the Effect of Cholestyramine on the Pharmacokinetics of LOXO-783 in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol